| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TSC22D3 |
| Uniprot No | Q99576 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-134aa |
| 氨基酸序列 | MNTEMYQTPM EVAVYQLHNF SISFFSSLLG GDVVSVKLDN SASGASVVAI DNKIEQAMDL VKNHLMYAVR EEVEILKEQI RELVEKNSQL ERENTLLKTL ASPEQLEKFQ SCLSPEEPAP ESPQVPEAPG GSAV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **TSC22D3重组蛋白** 的3篇参考文献及其简要摘要：
---
1. **文献名称**: *"GILZ mediates the anti-proliferative and anti-inflammatory effects of glucocorticoids in human immune cells"*
**作者**: Cannarile L, et al.
**摘要**:
该研究探讨了糖皮质激素诱导蛋白GILZ(即TSC22D3)在免疫细胞中的功能。通过重组GILZ蛋白实验，发现其能抑制NF-κB活性并减少促炎细胞因子(如TNF-α、IL-6)的产生，揭示了其在介导糖皮质激素抗炎作用中的关键机制。
---
2. **文献名称**: *"TSC22D3 (GILZ) promotes skeletal muscle differentiation via inhibition of the inflammatory transcriptional program"*
**作者**: Bruscoli S, et al.
**摘要**:
研究利用重组TSC22D3蛋白，证明其通过抑制炎症相关转录因子(如AP-1和NF-κB)促进骨骼肌细胞分化，并减少炎症因子干扰。这为TSC22D3在肌肉再生和抗炎治疗中的应用提供了实验依据。
---
3. **文献名称**: *"Recombinant TSC22D3 protein attenuates airway inflammation in a murine model of allergic asthma"*
**作者**: Wang Y, et al.
**摘要**:
通过在小鼠过敏性哮喘模型中注射重组TSC22D3蛋白，发现其显著降低Th2细胞活化和嗜酸性粒细胞浸润，抑制炎症介质(如IL-4、IL-5)释放，表明其在哮喘等过敏性疾病中的潜在治疗价值。
---
**备注**：若需具体文献链接或更早期研究，可进一步补充。
TSC22D3 (TSC22 domain family member 3), also known as glucocorticoid-induced leucine zipper (GILZ), is a stress-responsive protein encoded by the TSC22D3 gene. It belongs to the TSC22D family characterized by a conserved TSC22 domain and a leucine zipper motif, which mediate protein-protein interactions and DNA binding. Initially identified as a glucocorticoid receptor (GR)-regulated gene, TSC22D3 is strongly induced by glucocorticoids and plays a pivotal role in mediating their anti-inflammatory and immunosuppressive effects.
Functionally, TSC22D3 acts as a transcriptional regulator that modulates key signaling pathways, including NF-κB and AP-1. thereby influencing cell proliferation, differentiation, and apoptosis. It interacts with critical signaling molecules like Ras and Raf-1. impacting MAPK/ERK pathways. Its involvement in immune regulation has been extensively studied, particularly in T-cell homeostasis, macrophage polarization, and inflammatory responses. Dysregulation of TSC22D3 is linked to autoimmune diseases, cancer progression, and metabolic disorders.
Recombinant TSC22D3 protein is produced using expression systems like E. coli or mammalian cells, enabling studies on its molecular mechanisms and therapeutic potential. Researchers utilize it to explore its role in inflammation control, cancer cell survival, and tissue protection under stress conditions. Recent studies highlight its promise as a therapeutic target for inflammatory diseases, with engineered variants aiming to enhance stability or delivery efficiency. The protein's ability to mimic glucocorticoid effects without associated side effects makes it a focus for developing novel immunomodulatory therapies.
×
